Novo Nordisk (NVO) stock falls after issuing weak outlook for 2026 due to pricing pressure and competition. Q4 earnings beat.
Leaders of federally qualified clinics and safety-net hospitals joined local politicians to highlight what they say is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results